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The Journal of Immunology
Detection of Cell Surface Ligands for Human Synovial
gd T Cells
Cheryl Collins,* Yuan Lui,† Ana Mafalda Santos,† Bryan A. Ballif,‡ Anisha Mahalya Gogerly-
Moragoda,* Heather Brouwer,† Robin Ross,x Kuberan Balagurunathan,{ Sumana Sharma,‖
Gavin J. Wright,‖ Simon Davis,† and Ralph C. Budd*
Lack of understanding of the nature and physiological regulation of gd T cell ligands has considerably hampered full under-
standing of the function of these cells. We developed an unbiased approach to identify human gd T cells ligands by the production
of a soluble TCR-gd (sTCR-gd) tetramer from a synovial Vd1 gd T cell clone from a Lyme arthritis patient. The sTCR-gd was
used in flow cytometry to initially define the spectrum of ligand expression by both human tumor cell lines and certain human
primary cells. Analysis of diverse tumor cell lines revealed high ligand expression on several of epithelial or fibroblast origin,
whereas those of hematopoietic origin were largely devoid of ligand. This allowed a bioinformatics-based identification of
candidate ligands using RNAseq data from each tumor line. We further observed that whereas fresh monocytes and T cells
expressed low to negligible levels of TCR-gd ligands, activation of these cells resulted in upregulation of surface ligand expression.
Ligand upregulation on monocytes was partly dependent upon IL-1b. The sTCR-gd tetramer was then used to bind candidate
ligands from lysates of activated monocytes and analyzed by mass spectrometry. Surface TCR-gd ligand was eliminated by
treatment with trypsin or removal of glycosaminoglycans, and also suppressed by inhibition of endoplasmic reticulum–Golgi
transport. Of particular interest was that inhibition of glycolysis also blocked TCR-gd ligand expression. These findings demon-
strate the spectrum of ligand(s) expression for human synovial Vd1 gd T cells as well as the physiology that regulates their
expression. The Journal of Immunology, 2019, 203: 2369–2376.
F
ull understanding of gd T cell biology has been handi-
capped by ignorance of the ligands for most TCR-gd. gd
T cells reside at mucosal and epithelial barriers and often
accumulate at sites of inflammation with autoimmunity, infections,
or tumors (1). Evidence suggests that gd T cells provide protection
against infections with bacteria, viruses, and protozoans and are
generally beneficial in autoimmunity (1–17). In addition, a role for
gd T cells in the immune response against tumors in humans is
evident from a seminal study reporting that intratumoral gd T cells
are the most favorable prognostic immune population across 39
cancer types in humans (18). gd T cells are often highly lytic
against transformed proliferative cells, infected cells, and infil-
trating CD4+ T cells in inflammatory arthritis (9, 17, 19). They can
produce a variety of cytokines including IFN-g, TNF-a, and IL-17
(20), as well as insulin-like growth factor-1 (IGF1) and kerati-
nocyte growth factor (KGF) that promote epithelial wound repair
(21). These collective studies indicate that a principal function of
gd T cells is in response to tissue injury of various causes. It is,
thus, not surprising that gd T cells are often suggested to react to
host components that are upregulated or exposed during prolif-
eration or cell injury (22). As such, gd T cells may function in
tissue homeostasis and immunoregulation as much as in protection
from infection. Yet in the vast majority of cases, little if anything
is known regarding the nature of these self-components or whether
they actually engage the TCR-gd.
Whereas ab T cells recognize proteins that are processed into
peptides and presented on MHC molecules, the few proposed
ligands for gd T cells suggest that they recognize mostly intact
proteins directly, without MHC restriction. This makes them
highly attractive for immunotherapy. Despite the elaborate
mechanisms that ab T cells and B cells use to prevent autor-
eactivity, gd T cells have been frequently reported to respond to
autologous proteins. Furthermore, in contrast to other lymphocytes
that maximize the potential diversity of their receptors, gd T cells
frequently show limitations in their diversity. Thus, human gd
T cells comprise a subset of Vd2 T cells, the predominant gd in
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peripheral blood that respond to prenyl phosphates and certain alkyl
amines (23–25), and Vd1 T cells, which do not respond to these
compounds and often accumulate at epithelial barriers and sites of
inflammation (1). A similar limited repertoire occurs in the mouse
in which Vg5Vd1 cells colonize the epidermis, and a Vg6Vd1
subset colonizes the tongue, lung, and female reproductive tract
(21, 26). This restricted repertoire implies that TCR-gd ligands
may also be limited. This may provide for a more rapid response
and perhaps explain why, in contrast to ab T cells and B cells, it is
difficult to generate Ag-specific gd T cells by immunization with a
defined Ag.
Various ligands for gd T cells have been proposed, although
only a few have been confirmed to bind to TCR-gd, and these lack
any obvious similarity in structure. gd T cells for which ligands
have been identified include the murine gd T cell clone G8, which
recognizes the MHC class I–like molecules T10 and T22 (27), gd
T cells from mice infected with HSV that recognize herpes gly-
coprotein gl (28), a subset of murine and human gd T cells that
bind the algae protein PE (20), a human gd T cell clone G115 that
recognizes ATP synthase complexed with ApoA-1 (28), a human
gd T cell clone (Vg4Vd5) from a CMV-infected transplant patient
that recognizes endothelial protein C receptor (EPCR) (29), and
some human Vd1 T cells that recognize CD1d-sulfatide Ags (30).
However, to date no systematic process has been reported for
determining the spectrum of human TCR-gd ligands.
To provide an unbiased approach for the identification of can-
didate ligands for human gd T cells, we produced a biotinylatable
form of a soluble TCR-gd (sTCR-gd) from a synovial Vd1 gd
T cell clone of a Lyme arthritis patient. The tetramerized sTCR-gd
was used in flow cytometry to identify various cell types that
expressed candidate ligands. Initial analysis of 24 tumor cell lines
identified a set of nine ligand-positive tumors, enriched for those
of epithelial and fibroblast origin, and 15 ligand-negative tumors,
largely of hematopoietic origin. In addition, ligand was not
expressed by primary monocytes or T cells, although each could
be induced to express ligand following their activation. Ligand
expression was sensitive to trypsin digestion, revealing the protein
nature of the ligands, and was also reduced by inhibition of gly-
colysis. These findings provide a framework and strategy for the
identification of individual ligands for human synovial gd T cells.
Materials and Methods
Production of a sTCR-gd
Human synovial gd T cell clones from a Lyme arthritis patient were
produced as previously described (9, 31). One of these clones, Bb15, was
chosen for production of the sTCR-gd using modification of a previously
reported procedure (32, 33). Both TCR chains were produced as a single
transcript in a baculovirus vector. The pBACp10pH vector used contains
two back-to-back promoters, p10 and polyhedrin (Fig. 1A). The p10
promoter is followed by multiple cloning sites for the g-chain, and the
polyhedrin promoter is followed by multiple cloning sites for the d-chain.
Downstream of the g-chain, we placed a hexa-His tag for nickel column
purification, followed by a biotinylation sequence for tetramerization. The
g-chain and d-chain were PCR amplified using high fidelity polymerase
(Deep Vent Polymerase; New England Biolabs). Both TCR chain se-
quences were verified following the initial PCR amplification as well as
after insertion into the pBACp10pH vector. Virus encoding the sTCR-gd
was generated by cotransfection of Sf21 moth cells using the Sapphire
baculovirus DNA and Transfection kit (Orbigen) with the sTCR
pBACp10pH construct. Virus was harvested 6 d later and used as primary
stocks (P1 stock). Two additional rounds of viral amplification, P2 and P3,
were completed using midlog phase Sf21 cells (∼1.6 3 106 cells/ml)
allowed to adhere for 1 h before infecting at a multiplicity of infection
of 0.01 or 0.1 with P1 and P2 stock, respectively. After 72 h of infection,
culture medium was clarified by centrifugation (1000 3 g for 10 min) and
filtration (VacuCap 90PF 0.8/0.2 mm Supor membrane filter units; Pall,
Westborough, MA) before storing in the dark at 4˚C until use. Protein
production occurred in 12-l batches of midlog phase (∼1.6 3 106 cells/ml)
Hi5 cells growing in suspension (0.5 l of culture in 1 l spinner flasks) and
infected with P3 stock at a 1:50 dilution. Following 72 h of infection, cells
were removed by centrifugation and filtration as described above. The
filtered supernatant (∼12 l) containing secreted sTCR-gd was concentrated
to ∼100 ml before dialyzing against 1 l of nickel column loading buffer
(20 mM NaPhosphate buffer, pH 7.4, 20 mM imidazole, 0.5 M NaCl)
using a Pellicon diafiltration system with two 10K MWCO membranes
(MilliporeSigma, Burlington, MA) back down to ∼100 ml. After system
flushing, the final sample volume was ∼200 ml. It was then loaded onto
loading buffer–equilibrated His-Trap HP columns (GE Healthcare, Little
Chalfont, U.K.) at 100 ml per 2 3 5 ml columns. Columns were washed
with at least 10 column volumes of loading buffer until baseline absorption
was achieved. Bound proteins were eluted using a gradient from 20 to
500 mM imidiazole over 20 column volumes. Elution was monitored by
absorbance at 280 nM, and 1 ml fractions were collected. Fractions con-
taining the target protein were identified using SDS-PAGE gel analysis
using Coomassie Blue. High purity (.95%) sTCR-gd fractions were
pooled, dialyzed against PBS (pH 7.4), and frozen at 280˚C until used in
future studies. Yields were typically ∼1.0–2.5 mg/l of culture. Purified
sTCR-gd was then biotinylated using a biotin-protein ligase system
(Avidity) and tetramerized with streptavidin-PE (BioLegend) for FACS
staining. Verification of TCR-gd protein was confirmed by SDS-PAGE gel
analysis using Coomassie Blue as well as immunoblot using Abs to Vd1 or
Cg (Endogen).
Flow cytometry
Cells were stained with either sTCR-gd-PE (10 mg/ml) or negative controls
that included streptavidin-PE (10 mg/ml), IgG-PE (10 mg/ml) (BioLegend),
or a sTCRab-PE (a kind gift of Dr. M. Davis). Additional surface staining of
T cells consisted of CD4, CD8, CD19, and CD25 (BioLegend). Live–Dead
staining (BD Bioscience) was used to eliminate dead cells from analysis.
Samples were run on an LSRII flow cytometer (Becton Dickinson).
Purification and activation of human monocytes and T cells
and cell lines
Human monocytes were purified from human PBMC using CD14-labeled
magnetic beads, followed by column purification (Miltenyi Biotec) and
then cultured in RPMI complete medium with 10% FCS in the absence or
presence of either a Borrelia burgdorferi sonicate (10 mg/ml) or LPS
(1 mg/ml; Sigma-Aldrich) for 18 h. To some cultures were added TNF-a
(10 ng/ml) (BioLegend), anti-TNF-a (10 mg/ml) (BioLegend), IL-1b
(10 pg/ml) (Invitrogen), or anti–IL-1b (5 mg/ml) (R&D Systems). Cells
were then stained with the sTCR-gd tetramer. T cells from PBMC were
either used fresh or were activated with anti-CD3/anti-CD28 (each 10 mg/ml;
BioLegend) + IL-2 (50 U/ml; Cetus) and propagated for 3 d. Cells were then
stained with the sTCR-gd tetramer. Human PBMC were obtained using
an approved protocol from The University of Vermont Human Studies
Committee. Verified cell lines were obtained from American Type Culture
Collection. CHO cells deficient for glycosaminoglycans (GAGs) were
derived as previously described (34).
Bioinformatics analysis
Expression profiling (35) based on Illumina RNAseq technology (36) was
used to characterize the transcriptomes of 22 of the 24 tumor cell lines
examined (excluding bronchoepithelial cell line and 2fTGH). Expression
data for all known genes (37) were generated, and those genes whose
representation in tetramer-positive cell lines was significantly higher than
in negative cell lines were considered as candidate ligands.
Mass spectrometry analysis
Biotinylated sTCR-gd was bound to avidin magnetic beads and then in-
cubated with cell lysates from monocytes activated with B. burgdorferi
sonicate. Magnetic beads alone, without TCR-gd tetramer, with monocyte
lysates served as a negative control. After 4 h, beads were washed five
times, and bound proteins were then separated on polyacrylamide gels. Gel
lanes for each sample type were cut into 12 identical regions and diced into
1-mm cubes. In-gel tryptic digestion was conducted on each region as
previously described (38). Extracted peptides were subjected to liquid
chromatography tandem mass spectrometry (38), except that the analysis
was performed using an LTQ linear ion trap mass spectrometer (Thermo
Fisher Scientific, Waltham, MA). Tandem mass spectra were searched
against the forward and reverse concatenated human IPI database using
SEQUEST, requiring fully tryptic peptides, allowing a mass tolerance of
2 Da and mass additions of 16 Da for the oxidation of methionine and
71 Da for the addition of acrylamide to cysteine. SEQUEST matches in
the first position were then filtered by XCorr scores of 1.8, 2, and 2.7 for
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singly, doubly, and triply charged ions, respectively. Protein matches made
with more than two unique peptides were further considered. This list had
a peptide false discovery rate of ,0.01%.
Inhibition of glycolysis, transcription, translation, and
endoplasmic reticulum–Golgi transport or trypsin or
heparinases I–III treatment
Inhibition of glycolysis was performed using the 2-deoxyglucose (2-DG,
5mM; Sigma-Aldrich) for 48 h. Transcription and translationwere inhibited
using, respectively, actinomycin D (5mg/ml; ICN Biomedicals) or cycloheximide
(1 mg/ml; MilliporeSigma) for 18 h. Endoplasmic reticulum (ER)–Golgi
transport was blocked using brefeldin A (1:1000) or monensin (1:1400)
(BD Bioscience) for 18 h. Cell surface protein digestion was performed
using trypsin (Invitrogen) (13; 5–10 min, 37˚C.). GAGs were removed
from cells by treatment with heparinases I–III (2 mU/ml) for 30 min in
RPMI 1640 with no serum. The reaction was then stopped by the addition
of PBS–BSA.
Statistical analysis
The following statistical tests were used: unpaired Student t test when com-
paring two conditions, and one-way ANOVAwith Sidak test for correction for
multiple comparisons when comparing multiple variables across multiple
conditions.
Results
Production of a human synovial sTCR-gd
We previously produced a panel of synovial Vd1 gd T cells from
Lyme arthritis patients (9, 31). A representative clone, Bb15
(Vd1Vg9), was selected from which to clone its TCR-gd. The
pBACp10pH vector has been used previously to produce murine
sTCR-gd tetramers (33). It contains two back-to-back promoters,
p10 and polyhedrin, in which the p10 promoter is followed by
multiple cloning sites for inserting the g-chain, and the polyhedrin
promoter is followed by multiple cloning sites for inserting the
d-chain (Fig. 1A). Downstream of the g-chain we placed a hexa-
His tag for purification, followed by a biotinylation BRP sequence
for tetramerization with streptavidin-PE. Protein production was
undertaken in Hi5 cells followed by purification using His-Trap
HP columns. Fractions were analyzed by SDS-PAGE, and those
with protein of the correct size were pooled, with yields typically
of 1–2 mg/l of culture. A sample sTCR-gd preparation is shown in
Fig. 1B, stained with Coomassie Blue, showing bands of the ex-
pected size for the heterodimer under nonreducing (59 kDa) and
reducing conditions (30/28 kDa for the g- and d-chains, respec-
tively). The protein was stained by immunoblot with Abs to either
Vd1 or Cg (Fig. 1C) and also blocked anti-gd Ab staining of the
synovial gd T cell clones (Fig. 1D). The purified sTCR-gd was
then biotinylated and tetramerized with streptavidin-PE for use by
flow cytometry. As an additional measure of specificity, sTCR-gd
tetramer staining of a fibrosarcoma tumor cell line (2fTGH) could
be inhibited by anti-gd Ab but not control IgG (Fig. 1E). Finally,
staining of 2fTGH cells with the sTCR-gd tetramer was dose
dependent but did not increase with increasing dose on a negative
tumor line, Daudi (Fig. 1F).
Expression of sTCR-gd candidate ligand(s) varies among
cell lines
We initially used the sTCR-gd tetramer to screen a panel of 24 cell
lines from a variety of cell types. None of the cell lines stained
FIGURE 1. Production of human synovial sTCR-gd. (A) pBACp10pH vector containing the d-chain driven by the polyhedrin promoter and the g-chain
with hexa-His and biotinylation BRP sequences driven by the p10 promoter from gd T cell clone Bb15 (Vg9Vd1). (B) Sample of nickel NTA column-
purified sTCR-gd analyzed by SDS-PAGE under reducing and nonreducing conditions, and stained with Coomassie Blue. (C) Immunoblot of sTCR-gd
stained with anti-Vd1 or anti-Cg. (D) gd T cell clone Bb15 was stained with anti–TCR-gd Ab in the absence or presence of competing sTCR-gd. (E) The
fibrosarcoma cell line 2fTGH was stained with the sTCR-gd in the absence or presence of the indicated concentrations of anti-gd Ab or control IgG.
(F) Titration of sTCR-gd staining of the positively staining tumor line 2fTGH or negatively staining line Daudi. Number inserts indicate percent positively
staining cells. Findings are representative of three experiments.
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with the negative controls (IgG-PE, avidin-PE, or sTCR-ab
tetramer-PE), but the sTCR-gd tetramer gave a spectrum of
staining in which nine cell lines were strongly positive and the
other cell lines manifested low to undetectable surface staining
(Fig. 2). Of interest was that the positive group was enriched for
cell lines of epithelial and fibroblast origin, cell types known to
exist where gd T cells are often found, such as skin, intestines, and
synovium. With this information, expression profiling (35) using
available RNAseq was used to characterize the transcriptomes of
22 of the 24 tumor cell lines (RNAseq on the bronchoepithelial
and 2fTGH were not available). Expression data for all known
genes (37) were generated, and those genes whose representa-
tion in tetramer-positive cell lines was significantly higher than
in negative cell lines were considered to be candidate ligands.
This produced an initial list of candidate ligands for sTCR-gd
(Supplemental Table I).
Candidate sTCR-gd ligands are sensitive to trypsin and
reduced by inhibition of transcription, translation, ER–Golgi
transport, or removal of GAGs
We treated the positively staining cell lines with trypsin and noted a
complete disappearance of surface staining, as exemplified for
bronchoepithelial cells in Fig. 3A. Similar results were observed
with two additional tumor lines. This supports the view that the
TCR-gd ligand contains a protein component essential for rec-
ognition by the receptor. We also observed no increase in sTCR-
gd tetramer staining of cells (C1R or HeLa) expressing CD1a,
b, c, or d, nor with MICA/B (data not shown). Thus, at present
there is no evidence that the synovial Vd1 TCR-gd ligand is one of
these MHC class I–like molecules, at least bound to endogenous
molecules from these particular cell lines.
We further determined that surface TCR-gd ligand expression
was reduced by inhibition of protein translation or transcription
with, respectively, cycloheximide or actinomycin D (Fig. 3B).
Surface ligand was also considerably reduced by inhibition of
transport from the ER to Golgi using either brefeldin A or mon-
ensin (Fig. 3C). This further demonstrated the protein nature of
candidate TCR-gd ligands. Finally, we examined the extent to
which GAGs contribute to ligand binding by TCR-gd. This was
tested in two ways. Initially, the ligand-positive fibrosarcoma cell
line 2fTGH was either treated or not with heparinases I–III, which
removes most GAGs. This considerably reduced sTCR-gd tetra-
mer staining (Fig. 3D). This was further supported by the obser-
vation that sTCR-gd stained wild-type but not GAG-deficient
CHO cells (Fig. 3D).
sTCR-gd ligands are expressed by activated monocytes
In considering what primary cells might express ligand(s) for the
sTCR-gd, we first examined fresh monocytes, as we had observed
previously that following their activation with B. burgdorferi or
LPS, monocytes could activate the synovial gd T cell clones (31).
Consistent with these earlier findings, we observed that the
sTCR-gd tetramer did not stain freshly isolated human monocytes,
but following 24 h activation with a sonicate of B. burgdorferi or
LPS, there was a robust upregulation of sTCR-gd tetramer stain-
ing (Fig. 4). The same cells did not stain with negative controls
that included avidin-PE, IgG-PE, or a human sTCR-ab tetramer-
PE. Because activated monocytes are known to produce certain
cytokines, particularly TNF-a and IL-1b, we examined the pos-
sible influence of these cytokines on ligand expression. Curiously,
the low level of sTCR-gd tetramer staining of fresh monocytes
was reduced further with TNF-a, whereas ligand expression by
Borrelia-activated monocytes was not affected by the further ad-
dition of TNF-a or blocking anti–TNF-a Ab (Fig. 4B). By con-
trast, IL-1b increased ligand expression by fresh but not activated
monocytes, and blocking anti–IL-1b Ab partially inhibited ligand
expression by activated monocytes (Fig. 4C). Thus, sTCR-gd
ligand expression appears to be partly regulated by certain
monocyte-derived cytokines.
Given the induction of sTCR-gd ligand expression by activated
monocytes, we prepared lysates from Borrelia-activated mono-
cytes and then used the biotinylated sTCR-gd complexed with
avidin magnetic beads as a bait. Following incubation with the
monocyte lysates, the sTCR-gd was isolated by magnetic puri-
fication and washed five times; bound proteins were separated
on polyacrylamide gels, and gel slices were subjected to trypsin
FIGURE 2. sTCR-gd tetramer staining of a
cell line panel. A panel of 24 diverse cell lines
was stained with either sTCR-ab or sTCR-gd,
gated on live cells, and examined by flow
cytometry. Shown are examples of tumors
representing either (A) positive staining or (B)
negative staining with sTCR-gd, with the com-
plete list summarized below each example.
Number inserts indicate mean fluorescence in-
tensity of entire histogram. Findings are repre-
sentative of four experiments.
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digestion and analyzed by mass spectrometry. Avidin magnetic
beads alone incubated with monocyte lysates served as a negative
control. This analysis yielded 291 unique proteins (Supplemental
Table II). When compared with the list produced by the RNAseq
bioinformatics approach of the tumor lines, 16 proteins were
found in common (Supplemental Table III). Of interest is that two
of these, Annexin A2 and heat shock protein 70, have previously
been proposed as gd ligands (39–41).
sTCR-gd ligands are expressed by activated T cells
We further analyzed freshly isolated PBL from three individuals of
various ages (28–66). This consistently revealed that fresh CD8+
FIGURE 3. sTCR-gd ligand is sensitive to protease, blockers of ER–Golgi transport, translation, or transcription and contains GAGs. The human
bronchoepithelial cell line was either untreated or treated with (A) trypsin for 15 min, (B) untreated or treated for 18 h with cycloheximide or actinomycin
D, or (C) untreated or treated for 18 h with brefeldin A or monensin. Cells were then stained with sTCR-gd tetramer. (D) The 2fTGH fibrosarcoma cell line,
wild-type CHO cells, or GAG-deficient CHO cells were either untreated or treated with a combination of heparinases I–III for 30 min and then stained with
sTCR-gd tetramer. Number inserts indicate mean fluorescence intensity of entire histogram. Findings are representative of three experiments.
FIGURE 4. TCR-gd ligand is induced on human monocytes following activation. (A) Freshly isolated monocytes were either unstimulated or activated
with B. burgdorferi or LPS for 18 h and then stained with the indicated reagents and analyzed by flow cytometry. (B and C) Fresh monocytes or monocytes
activated with Borrelia were incubated in the presence of medium alone or TNF-a or blocking anti-TNF-a (B) or IL-1b or blocking anti–IL-1b (C).
Number inserts indicate percent positively staining cells. Error bars represent SEM. Findings are representative of four experiments.
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T cells exhibited negligible sTCR-gd staining, whereas a subset of
fresh CD4+ T cells manifested modest levels of sTCR-gd staining
(Fig. 5A). In contrast to the freshly isolated T cells, following 3 d
activation with anti-CD3/CD28 + IL-2, we observed that a subset
of both CD4+ and CD8+ T cells now displayed high levels of
sTCR-gd staining (Fig. 5B). Both the proportion of cells
expressing ligand and the density was higher on activated CD4+
T cells compared with CD8+ T cells. Given that in vitro–activated
proliferating T cells express sTCR-gd ligand, we considered that
the subset of fresh CD4+ T cells expressing ligand might also
represent a proliferative subset. One of the most rapidly prolifer-
ative T cell subsets in vivo is T regulatory cells (Treg) (42). Treg
can be identified as a subset of fresh CD4+ T cells expressing
CD25. Indeed, when we subset fresh human CD4+ T cells based
on CD25 expression, sTCR-gd tetramer staining was again ob-
served preferentially by the CD25+ subset (Fig. 5C).
TCR-gd ligand expression is partly dependent upon glycolysis
The finding that fresh monocytes and T lymphocytes expressed low
to negligible levels of sTCR-gd ligand(s), but upregulated ex-
pression following activation, raised the possibility that this might
reflect the known induction of glycolysis following activation of
T cells, monocytes, or dendritic cells (43, 44) and the resultant
synthetic capacity promoted by glycolysis (45). This notion is
supported by the fact that ligand-expressing Treg are also highly
glycolytic (42). We thus examined this question in two ways. First,
we exposed activated T cells to 2-DG, an inhibitor of glycolysis.
This reduced expression of both CD25 and sTCR-gd ligand
(Fig. 6A). Second, we distinguished between activated T cells on
day 3 based on their expression of CD25, as this identifies cells
responsive to IL-2 and are hence most glycolytic (45). As shown
in Fig. 6B, CD25+ T cells expressed sTCR-gd ligand whereas the
CD252 subset was devoid of ligand expression. Of further note is
that within the CD25+ subset, CD4+ T cells again expressed more
ligand than CD8+ T cells (Fig. 6B). We extended this analysis to
the ligand-positive tumor 2fTGH and observed that 2-DG also
resulted in reduced ligand expression in these cells (Fig. 6C).
Discussion
To our knowledge, the current findings provide the first unbiased
characterization of the spectrum of ligand expression for human
synovial Vd1 gd T cells. The range of ligand expression may reflect
the various locations and seemingly diverse functions attributed to
gd T cells. For example, ligand induction by B. burgdorferi– or
LPS-activated monocytes parallels their known ability to activate
synovial gd T cell clones (9, 31). In addition, ligand expression by
fresh CD4+ but not CD8+ T cells also correlates with our previous
observations that Lyme arthritis synovial gd T cells suppress by
cytolysis the expansion of synovial CD4+ but not CD8+ T cells in
response to B. burgdorferi (9). Finally, defining the spectrum of
tumor cell types that express TCR-Vd1 ligands may help explain
which tumors contain Vd1 gd T cells and impact their effective-
ness as immunotherapy. The collective findings are also most
consistent with the view that gd T cells respond to self-proteins as
much as or possibly more than foreign proteins. Although these
results were obtained using a sTCR-gd tetramer from a single
synovial gd T cell clone, the fact that it shares a common Vd1
chain found on most synovial gd T cells (9), as well as gd T cells
found in intestinal epithelium (1, 10, 21), several tumors (18),
and cells expanded in PBL following certain infections such as
HIV (46, 47) and CMV (29), suggests the possibility that Vd1 gd
T cells from these other sources may share a common physiology
of ligand expression.
Previous studies of ligands for murine and human gd T cells
have come largely from the identification of individual molecules
that activate a specific gd T cell clone (27–30). Although this has
been successful in some instances, the current study applied a
broader approach of using a sTCR-gd tetramer in an unbiased
fashion to identify the spectrum of ligand expression and how they
are regulated. This approach also provided two independent methods
by which to identify candidate ligands. One method used RNAseq
transcriptome analysis from 22 tumor cell lines to match genes in-
creased in positively staining tumors and decreased in negatively
staining tumors. The second approach used the sTCR-gd tetramer as
a bait to bind ligands from lysates of activated monocytes and then
FIGURE 5. sTCR-gd tetramer stains a subset of
activated human T cells and Treg. PBL were stained
with Abs to CD4 and CD8 as well as with sTCR-ab
tetramer-PE or sTCR-gd tetramer-PE either (A)
freshly isolated or (B) 3 d after activation with anti-
CD3/CD28 + IL-2. Number inserts indicate the
percentages of T cells staining negatively or
positively with sTCR-gd tetramer, as a portion of
the total CD4+ or CD8+ subsets, as well as mean
fluorescence intensity (MFI) in some cases. Findings
are representative of six experiments. (C) Freshly
isolated PBL were stained with anti-CD4, anti-CD25
or isotype control, and streptavidin-PE (SA-PE) or
sTCR-gd-PE. Shown are cells gated on CD4 expres-
sion. Number inserts indicate MFI of sTCR-gd-PE
staining for CD25+ and CD252 subsets. Findings are
representative of two experiments.
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identify the bound proteins by mass spectrometry. It is of con-
siderable intertest that among these two sets of candidate ligands
were 16 in common, two of which, Annexin A2 and heat shock
protein 70, have been previously proposed as ligands for gd
T cells (39–41). By contrast, surface sTCR-gd tetramer binding
was eliminated by treatment with trypsin or removal of GAGs, and
also suppressed by inhibition of ER–Golgi transport, suggesting
the involvement of a combination of protein and GAGs in tet-
ramer binding. Future studies will explore through knockdown
and transfection methods whether any of the candidate ligands
we have identified activate the original gd T cell clone and the
extent to which GAG/glycoprotein binding may or may not be a
confounder.
Although the findings thus far have not determined whether there
is one or several synovial Vd1 TCR-gd ligands, they do provide a
framework for understanding the distribution and regulation of
ligand expression, which is critical for better understanding of gd
T cell biology. For example, gd T cells have been implicated in the
defense against a variety of infections (2–7), which is consistent
with our finding that different TLR agonists induce TCR-gd ligand
expression on monocytes. Similar studies using a murine sTCR-gd
also found ligands induced with bacterial infection (21). In addi-
tion, gd T cells have been found to generally alleviate various
autoimmune models (12–15), which may be consistent with the
expression of ligand by a subset of activated CD4+ T cells.
The induction of TCR-gd ligand expression by activation of
primary monocytes or T cells, as well as ligand expression by a
variety of highly proliferative tumor cell lines, suggested that the
metabolic state of cells may influence their ability to express
TCR-gd ligands. Activation of monocytes and T cells is known to
induce a metabolic switch to glycolysis to provide the synthetic
capacity for proliferation (43, 44). In addition, Treg, which are
known to be glycolytic in vivo (42), spontaneously expressed
ligand. Moreover, most tumors are highly glycolytic, and the in-
hibition of glycolysis in these cells also reduced ligand expression.
Collectively, these findings suggest that some gd T cells may
function to survey and regulate highly proliferative cells.
It is of some interest that the cell lines bearing high levels of
TCR-gd ligand expression were enriched for those of epithelial
and fibroblast origin, because Vd1 gd T cells are typically found at
epithelial barriers, such as skin or intestinal epithelium, as well as
in inflamed synovium, which is rich in fibroblasts (48). By con-
trast, sTCR-gd ligand expression was noticeably absent from most
cell lines of hematopoietic origin. The spectrum of cell line
staining with the human synovial sTCR-gd also bears consider-
able similarity to previous results using a murine sTCR-gd, which
strongly stained epithelial and fibroblast tumors, and less well
tumors of hematopoietic origin (33). These same murine sTCR-gd
also stained macrophages activated by TLR2 or TLR4 stimuli,
similar to our findings with monocytes activated by Borrelia or
LPS (49). Furthermore, staining of macrophages by the murine
sTCR-gd was also not affected by the absence of b2-microgloublin,
suggesting little or no contribution of ligand by classical or non-
classical MHC class I molecules. This agrees with our findings that
the human synovial sTCR-gd tetramer staining was not affected by
the presence or absence of CD1 or MICA/B molecules.
The findings in this study were made using primary cells and
tumor cell lines. Future studies will attempt to extend these results
to analyses of sTCR-gd tetramer histologic staining of primary
tissues as well as tumors and inflamed synovium to determine the
spectrum of TCR-gd ligand expression at these sites. Screening
primary tumors for binding of sTCR-gd tetramer may also help
identify tumors that may benefit from immunotherapy with Vd1
gd T cells. In addition, identifying the ligands in inflamed syno-
vium or intestinal epithelium will provide therapeutic strategies
for manipulating the function of infiltrating gd T cells.
FIGURE 6. TCR-gd ligand expres-
sion parallels glycolysis. (A and B) PBL
were activated with anti-CD3/CD28 +
IL-2 in the absence or presence of 2-DG
(5 mM). On day 3, cells were stained
with Abs to CD4, CD8, CD25, and
sTCR-gd tetramer-PE. Shown in (A) are
the levels of CD25 and TCR-gd ligand
without or with 2-DG. Shown in (B) is
the expression of TCR-gd ligand in
CD4+ or CD8+ subsets based on surface
CD25. (C) 2fTGH cells were cultured
for 48 h in either regular medium or
medium plus 2-DG (5 mM). Cells were
then stained with TCR-ab or TCR-gd.
Number inserts indicate mean fluores-
cence intensity (MFI) of sTCR-gd-PE
staining. Findings are representative of
three experiments.
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